RxDoctor Payments Data

Gretchen Conley

Adult Health · Indianapolis, INNPI 1346217684

Payments from drug & device makers

$867in general payments, 2019–2025

Across 59 payments — averaging $14.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$332
  • AstraZeneca$283
  • Merck$114
  • Xeris Pharmaceuticals, Inc.$31
  • Boston Scientific$30
  • Lilly USA, LLC$27
  • plus $49 from 3 others

What the payments were for

  • Food & beverage$867100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$867 in reported general payments places this provider in the 65th percentile of 391 adult health providers in Indiana.

See all adult health providers in Indiana

Medicare billing

Part B allowed, 2024
$18,934
Medicare patients
148
Services billed
324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide92$174,125
MounjaroTirzepatide93$142,426
JardianceEmpagliflozin54$52,360
FarxigaDapagliflozin Propanediol28$34,817
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog19$31,578
TrulicityDulaglutide16$27,627
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/727$25,719
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$24,728
RybelsusSemaglutide11$21,868
JanuviaSitagliptin Phosphate18$15,673
Novolog FlexpenInsulin Aspart36$13,858
Lantus SolostarInsulin Glargine,hum.Rec.Anlog58$10,579
Humalog Kwikpen U-100Insulin Lispro23$7,259
Repatha SureclickEvolocumab11$6,374
Nano 2nd Gen Pen NeedlePen Needle, Diabetic53$5,426

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$332$195,992103 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$27$173,782127 claims
AstraZenecaFarxiga$283$34,81728 claims
MerckJanuvia$114$15,67318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 391 adult health providers in Indiana.

Other adult health in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →